Serdexmethylphenidate and Dexmethylphenidate
Brand names: Azstarys · Active ingredient: Serdexmethylphenidate Chloride, Dexmethylphenidate Hydrochloride
In short: AZSTARYS is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years of age and older. Limitations of Use The use of AZSTARYS is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence
What is Serdexmethylphenidate and Dexmethylphenidate used for?
AZSTARYS is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years of age and older.
Limitations of Use
The use of AZSTARYS is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage .
âš Boxed warning (FDA's strongest warning)
AZSTARYS has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including AZSTARYS, can result in overdose and death , and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.
Before prescribing AZSTARYS, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout AZSTARYS treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction .
Serdexmethylphenidate and Dexmethylphenidate dosage
Prior to treating patients with AZSTARYS, assess:
for the presence of cardiac disease (i.e., perform a careful history, family history of sudden death or ventricular arrhythmia, and physical exam) .
the family history and clinically evaluate patients for motor or verbal tics or Tourette’s syndrome before initiating AZSTARYS .
Pediatric Patients 6 to 12 years of age
The recommended starting dosage of AZSTARYS is 39.2 mg serdexmethylphenidate/7.8 mg dexmethylphenidate once daily in the morning.
The dosage may be increased after one week to a dosage of 52.3 mg serdexmethylphenidate/10.4 mg dexmethylphenidate per day, or decreased after one week to a dosage of 26.1 mg serdexmethylphenidate/5.2 mg dexmethylphenidate per day, depending on response and tolerability.
Maximum recommended dosage is 52.3 mg serdexmethylphendiate/10.4 mg dexmethyphenidate once daily.
Adults and Pediatric Patients 13 to 17 years of age
The recommended starting dosage of AZSTARYS is 39.2 mg serdexmethylphenidate/7.8 mg dexmethylphenidate once daily in the morning.
Increase the dosage after one week to a dosage of 52.3 mg serdexmethylphenidate/10.4 mg dexmethylphenidate per day, depending on response and tolerability.
Maximum recommended dosage is 52.3 mg serdexmethylphenidate/10.4 mg dexmethylphenidate once daily.
Administer AZSTARYS orally once daily in the morning with or without food
.
AZSTARYS capsules may be taken whole, or opened and the entire contents sprinkled into 50 mL of water or over 2 tablespoons of applesauce. Consume all the drug/food mixture immediately or within 10 minutes of mixing; do not store for future use
.
If switching from other methylphenidate products, discontinue that treatment, and titrate with AZSTARYS using the titration schedule described above.
Do not substitute AZSTARYS for other methylphenidate products on a milligram-per-milligram basis because these products have different pharmacokinetic profiles from AZSTARYS and may have different methylphenidate base composition
.
If paradoxical aggravation of symptoms or other adverse reactions occur, reduce dosage or, if necessary, discontinue AZSTARYS. If improvement is not observed after appropriate dosage adjustment over a one-month period, discontinue AZSTARYS.
How to take Serdexmethylphenidate and Dexmethylphenidate — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Abuse, Misuse, and Addiction
Educate patients and their families about the risks of abuse, misuse, and addiction of AZSTARYS, which can lead to overdose and death, and proper disposal of any unused drug
.
Advise patients to store AZSTARYS in a safe place, preferably locked, and instruct patients to not give AZSTARYS to anyone else.
Risk to Patients with Serious Cardiac Disease
Advise patients that there are potential risks to patients with serious cardiac disease, including sudden death, with AZSTARYS use. Instruct patients to contact a healthcare provider immediately if they develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease
.
Increased Blood Pressure and Heart Rate
Advise patients and their caregivers that AZSTARYS can elevate blood pressure and heart rate
.
Psychiatric Adverse Reactions
Advise patients and their caregivers that AZSTARYS, at recommended doses, can cause psychotic or manic symptoms, even in patients without a prior history or psychotic symptoms or mania
. …
Warnings & precautions
Do not take this medicine if: AZSTARYS is contraindicated in patients:
with known hypersensitivity to serdexmethylphenidate, methylphenidate, or other components of AZSTARYS. Bronchospasm, rash, and pruritus have been reported in patients who received AZSTARYS. Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other methylphenidate products
.
receiving concomitant treatment with monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOI, because of the risk of hypertensive crisis
.
AZSTARYS has a high potential for abuse and misuse. The use of AZSTARYS exposes individuals to the risks of abuse and misuse, which can lead to the development of a substance use disorder, including addiction. AZSTARYS can be diverted for non-medical use into illicit channels or distribution
. Misuse and abuse of CNS stimulants, including AZSTARYS, can result in overdose and death
,
and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.
Before prescribing AZSTARYS, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks and proper disposal of any unused drug. Advise patients to store AZSTARYS in a safe place, preferably locked, and instruct patients to not give AZSTARYS to anyone else. Throughout AZSTARYS treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction.
Sudden death has been reported in patients with structural cardiac abnormalities or other serious cardiac disease who were treated with CNS stimulants at the recommended ADHD dosage. …
Serdexmethylphenidate and Dexmethylphenidate side effects
The following are discussed in more detail in other sections of the labeling:
Abuse, Misuse, and Addiction
[see Boxed Warning, Warnings and Precautions
(5.1), and Drug Abuse and Dependence
(9.2,
9.3)]
Known hypersensitivity to methylphenidate or other ingredients of AZSTARYS
Hypertensive Crisis with Concomitant Use of Monoamine Oxidase Inhibitors
Risks to Patients with Serious Cardiac Disease
Increased Blood Pressure and Heart Rate
Psychiatric Adverse Reactions
Priapism
Peripheral Vasculopathy, including Raynaud's Phenomenon
Long-Term Suppression of Growth in Pediatric Patients
Acute Angle Closure Glaucoma
Increased Intraocular Pressure and Glaucoma
Motor and Verbal Tics, and Worsening of Tourette’s Syndrome
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Adverse Reactions in Studies with Other Methylphenidate Products in Pediatric Patients and Adults with ADHD
Commonly reported (≥ 5% of the methylphenidate group and at least twice the rate of the placebo group) adverse reactions from placebo-controlled trials of methylphenidate products include: decreased appetite, decreased weight, nausea, abdominal pain, dyspepsia, vomiting, insomnia, anxiety, affect lability, irritability, dizziness, increased blood pressure, and tachycardia. …
Drug interactions
Table 1presents clinically important drug interactions with AZSTARYS.
Monoamine Oxidase Inhibitors (MAOIs)
Clinical Impact | Concomitant use of MAOIs and CNS stimulants, including AZSTARYS, can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure
.
Intervention | Do not administer AZSTARYS concomitantly with MAOIs or within 14 days after discontinuing MAOI treatment
Antihypertensive Drugs
Clinical Impact | AZSTARYS may decrease the effectiveness of drugs used to treat hypertension
.
Intervention | Monitor blood pressure and adjust the dosage of the antihypertensive drug, as needed.
Halogenated Anesthetics
Clinical Impact | Concomitant use of halogenated anesthetics and AZSTARYS may increase the risk of sudden blood pressure and heart rate increase during surgery.
Intervention | Avoid use of AZSTARYS in patients being treated with anesthetics on the day of surgery.
Risperidone
Clinical Impact | Combined use of methylphenidate with risperidone when there is a change, whether an increase or decrease, in dosage of either or both medications, may increase the risk of extrapyramidal symptoms (EPS).
Intervention | Monitor for signs of EPS.
About this medicine
AZSTARYS (serdexmethylphenidate and dexmethylphenidate) capsules contain dexmethylphenidate, a CNS stimulant, and serdexmethylphenidate, a prodrug of dexmethylphenidate.
AZSTARYS capsules are intended for oral administration and each capsule contains a fixed molar ratio of 30% dexmethylphenidate and 70% serdexmethylphenidate.
AZSTARYS contains 26.1/5.2, 39.2/7.8, or 52.3/10.4 mg of serdexmethylphenidate/ dexmethylphenidate (equivalent to 28/6, 42/9, or 56/12 mg of serdexmethylphenidate chloride/ dexmethylphenidate hydrochloride, respectively. The combined molar dose of serdexmethylphenidate and dexmethylphenidate in each dosage strength of AZSTARYS is equivalent to 20, 30, or 40 mg dexmethylphenidate hydrochloride, respectively (equivalent to 17.3, 25.9 or 34.6 mg dexmethylphenidate free base, respectively).
The chemical name of serdexmethylphenidate chloride is 3-(((
1S)-1-carboxy-2-hydroxyethyl)carbamoyl)-1-((((
2R)-2-(2-(
1R)-methoxy-2-oxo-1-phenylethyl)piperidine-1-carbonyl)oxy)methyl)pyridinium chloride. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 00b5e716-5564-4bbd-acaf-df2bc45a5663. Read the full official label on DailyMed.
Related medicines
Tirzepatide Methylphenidate Lisdexamfetamine Amphetamine Orlistat Benzphetamine Phendimetrazine Centanafadine